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The Epstein–Barr nuclear antigen (EBNA)-3 and EBNA-4 proteins are thought to act as transcriptional transactivators.
The yeast two-hybrid system and coimmunoprecipitation were used to demonstrate that EBNA-3 and -4 associate with the
DNA-binding protein RBP-2N, an isoform of RBP-Jk. A comparison between EBNA-3, EBNA-4, and EBNA-6 binding to RBP-
2N indicated that EBNA-3 enhanced b-galactosidase activity 4-fold more than EBNA-6 and 30-fold more than EBNA-4.
Assay of RBP-2N deletion mutants demonstrated that EBNA-3 binds to regions of RBP-2N which are distinct from those to
which EBNA-2 and -6 interact, whereas EBNA-4 binds to the same region of RBP-2N as EBNA-2 and -6 (amino acids 159–
331 of RBP-2N). Interaction of both A- and B-type EBNA-3 with RBP-2N was also demonstrated by immunoprecipitation.
RT-PCR analysis of a panel of B cell lymphomas and lymphoblastoid cell lines demonstrated that higher levels of RBP-2N
were expressed, in comparison to RBP-Jk, indicating that RBP-2N is a major isoform expressed in B cells. These results
suggest that all the EBNA-3 family proteins lead to transcriptional regulation via interaction with RBP-2N. q 1996 Academic
Press, Inc.
INTRODUCTION These results suggested that the transcriptional activity
of EBNA-3 and -6 is due to binding to an intermediary
Epstein–Barr virus (EBV), the causative agent of infec- protein. EBNA-6 has been shown to modulate transcrip-
tious mononucleosis, has been implicated in the patho- tion through interaction with the DNA-binding protein
genesis of a number of lymphoid and epithelial malignan- RBP-Jk (Marshall et al., 1995; Robertson et al., 1995), also
cies. The growth-transforming activity of this herpesvirus known as CBF1. Using the yeast two-hybrid system our
appears to be the major factor contributing to these dis- group has recently demonstrated that EBNA-6 interacts
ease states. Following infection, the coordinate expres- with an isoform of RBP-Jk, RBP-2N, through a region
sion of a number of Epstein–Barr nuclear antigens similar to that used by EBNA-2 (Young et al., submitted).
(EBNAs 1–6) and membrane proteins (LMP-1 and LMP- Gel shift analysis indicated that EBNA-2, -4, and -6 inter-
2) acts to initiate and maintain B cell growth and transfor- act with RBP-Jk and lead to transcriptional modulation
mation (reviewed in Kieff et al., 1990). Two types of EBV of reporter genes (Marshall et al., 1995; Robertson et
have been identified which show sequence divergence al., 1995). More recently, using immunoprecipitation, the
in the EBNA-2, -3, -4, and -6 genes at both the DNA and amino-terminal domains of EBNA-3, -4, and -6 have been
the amino acid level. shown to interact with RBP-Jk (Robertson et al., 1996). In
The EBNA-3 family of proteins, EBNA-3, -4, and -6 (also addition, Xhao et al. (1996) demonstrated that RBP-2N
known as EBNA-3a, -3b, -3c) have a similar genomic and RBP-Jk interact with EBNA-6 in the yeast two-hydrid
organisation and share structural homologies (Le Roux system. However, the region of interaction with RBP-Jk
et al., 1994). The function of the individual proteins has was shown to be a 74-amino-acid domain that is con-
not been fully characterised; however, it has been shown served between the EBNA-3 family proteins.
that EBNA-3 and -6 are essential for viral transformation RBP-2N was originally isolated from a mouse pre-B
(Tomkinson et al., 1992, 1993). Recombinant expression cell line cDNA library and differs from RBP-Jk only in the
of EBNA-4 has been found to enhance the survival of first exon, but is homologous in the remaining 10 exons
cells which are prone to undergo apoptotic cell death (Kawaichi et al., 1992). RBP-Jk contains a transcriptional
(Silins and Sculley, 1995). Sample et al. (1994) have repression domain and it is thought to act by binding
shown previously that EBNA-3 and -6 are unable to di- DNA and inhibiting transactivation of genes (Hseih and
rectly interact with DNA, but DNA-binding activity was Hayward, 1995). RBP-2N has also been identified as a
exhibited using crude protein lysates (Kallin et al., 1986). transcriptional repressor with a DNA recognition se-
quence, 5*-TGGGAAAGAA (Dou et al., 1994), different
from that of RBP-Jk. The Drosophila homologue of RBP-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 61-7-3362-0106; E-mail: keniaK@qimr.edu.au. 2N, suppressor of hairless (Schweisguth and Posakony,
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1992) is involved in the regulation of neurogenic expres- sites added. The PCR product was digested with BamHI
and ligated into the BamHI site of pGBT9, containing thesion, suggesting a role of RBP-2N in the regulation of
gene expression. second exon of EBNA-3A. The orientation of the insert
and coding sequence were confirmed by restriction anal-The yeast two-hybrid system provides a method
whereby in vivo protein–protein interactions can be iden- ysis and DNA sequencing using primers specific for the
pGBT9 plasmid (Clontech Laboratories).tified and characterised through reconstitution of the ac-
tivity of the GAL4 transcriptional activator (discussed in pGBT9-E4. The 3.1-kb CelII (Klenow treated)– SalI frag-
ment of plasmid pSG5/EBNA-4 (a kind gift from E. S. Ro-Chien et al., 1991). Interacting proteins, expressed in
fusion with the GAL4 activation and DNA-binding do- bertson, Boston; containing the A-type EBNA-4 cDNA),
was ligated into SmaI–SalI-restricted pUC19. From thismains, lead to the transcriptional activation of the b-
galactosidase gene containing the binding site for GAL4. construct, a 3.1-kb EcoRI–SalI fragment was obtained
and ligated into the expression vector pGBT9 (Clontech)The level of b-galactosidase activity can be influenced
by: (1) the expression levels of each protein within the previously digested with EcoRI–SalI. This vector was
then digested with SacI, Klenow treated, and religatedyeast; (2) how the proteins interact, i.e., some interactions
may lead to better GAL4 association, and therefore to in order to produce the correct reading frame for the
EBNA-4 gene. The resulting plasmid pGBT9-E4 ex-increased b-galactosidase activity; and (3) the strength/
affinity of interaction between the proteins, whereby pressed a fusion protein of the GAL4-binding domain
and the EBNA-4 protein missing its amino-terminal fivestronger interactions lead to greater activity. The influ-
ence of each of these parameters needs to be consid- amino acids. The cloning procedure was verified by DNA
sequencing.ered when comparing and contrasting binding affinities
between proteins in the yeast system. The yeast two- EBO-EBNA3 (A and B). The 10.5-kb shuttle vector EBO-
pLPP (Margolskee et al., 1988), which contains the oriP/hybrid system, therefore, not only identifies protein–pro-
tein interactions, but also allows the characterisation of EBNA-1 replicon for episomal maintenance of the vector,
the hygromycin resistance gene for eukaryotic selection,binding properties.
In this report we demonstrate, using the yeast two- and an SV40 transcription cassette, was used for con-
structing plasmids stably expressing the EBNA-3 openhybrid system, that the EBNA-3 family of proteins inter-
acts with the RBP-2N isoform of RBP-Jk. reading frames of either A-type or B-type EBV. The EBO-
EBNA-3A plasmid encoding the A-type EBNA-3 has been
described elsewhere (Kienzle et al., 1996b). To prepareMATERIALS AND METHODS
the EBO-EBNA-3B expression vector, a 3.5-kb HindIII –
Yeast two-hybrid system CelII (Klenow treated) fragment was subcloned from
plasmid pUC19HIIIE-B (containing the genomic HindIIIEThe cDNA library was prepared from an EBV-trans-
fragment of B-type EBV strain Ag876), and was ligatedformed human B cell line and cloned into the shuttle
into a SalI (Klenow treated) digest of EBO-pLPP.expression vector pACT (Clontech). The cDNA LCL li-
brary screen was performed in yeast strain HF-7C and RBP-2N constructs
the cotransformations were performed in yeast strains
The construction of the RBP-2N deletion mutants hasY190 or SFY-526. All methods used and reagents pre-
been described previously (Young et al., submitted).pared for the cDNA library screen and cotransformations
Briefly, deletion mutants of RBP-2N were generated byin yeast and b-galactosidase assays (filter and liquid)
restriction digestion of full length RBP-2N and cloned intowere performed according to the manufacturer’s instruc-
the vector pGAD424 (Clontech). The correct orientationtions (Clontech Laboratories).
and insertion of fragments were all confirmed by DNA
sequencing.EBNA vector constructs
pGBT9-E3A. The coding sequence of EBNA-3A (B95.8 DNA sequencing
virus) was cloned into pGBT9 (plasmid containing the
DNA sequencing reactions were performed accordingGAL4 DNA-binding domain) in two steps. The majority
the protocol in the PRISM Ready Reaction DyeDeoxyof the second exon of EBNA-3 was excised from pB-E3A
terminator cycle sequencing kit (Applied Biosystems,(contains the EBNA-3 cDNA; Wang et al., 1987) using
Inc., Foster City, CA). The reactions were then analysedBamHI and SalI (cleaves in the vector MCS). This frag-
using the automated Applied Biosystems Model 373Ament was then ligated into BamHI–SalI-restricted pGBT9
DNA sequencing system.vector. The first exon and start of the second exon (up
to the BamHI site of EBNA-3) were generated by PCR
Cell lines and maintenance
amplification, using EBNA-3-specific primers, 5*-AAG-
GATCCTGCAGATGGACAAGGACAGG-3* and 5*-ACA- The EBV-negative Burkitt’s lymphoma cell lines (BLs)
BJAB (Klein et al., 1974) and dG75 (Ben Bassat et al.,TCTCGGTATTTGAAATCTGGGATCCGA-3* with BamHI
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1977), the EBV-positive BLs MUTU I and III (Gregory et incubated with either mouse anti-EBNA-3 monoclonal an-
tibody (Rowe et al., 1989) or EBV-positive human seraal., 1990), the lymphoblastoid cell lines (LCLs) QIMR-ISM/
Wil, QIMR-PGP/BL74, and QIMR-KT/B95.8 (produced by MCr (1:100 dilution) for the detection of EBNA-3. Rat anti-
RBP-Jk monoclonal antibody (T6719; a gift from T. Honjo,infection of human B lymphocytes from donors ISM, PGP,
and KT with the virus strains Wil, BL74, or B95.8), and Kyoto University, Japan) was used for the detection of
RBP-Jk. After washing with PBS containing 0.05% Tweenthe promyelocytic HL-60 cells (Collins et al., 1977) were
maintained in RPMI 1640 supplemented with 10% fetal 20 (PBS–Tween), the filters were incubated with a 1:1000
dilution of either sheep anti-human IgG HRP (Silenus,calf serum, benzylpenicillin (0.7 mg/ml), and streptomycin
(1 mg/ml) at 377 in 5% CO2 atmosphere. When culturing Australia) or sheep anti-mouse HRP (Amersham, UK) for
detection of EBNA-3, or rabbit anti-rat HRP (Dako, Den-the transfected cell lines 500 mg/ml hygromycin was
added. mark) to detect RBP-Jk/RBP-2N. After subsequent wash-
ing with PBS–Tween, detection was performed using the
EBNA-3B transfection of dG75 cells ECL method according to the manufacturer’s instructions
(Amersham, UK).Transfection of the EBV-negative Burkitt’s lymphoma
cell line dG75 with the expression vectors was performed
RBP-2N/RBP-Jk RT-PCR analysisas recently outlined (Silins and Sculley, 1994) using lipo-
fectin-mediated transfer of the plasmid DNA. Surviving A detailed description of the reverse transcription (RT)-
cell clones and heterogenous bulk cultures were se- PCR amplification and product analysis was outlined re-
lected and maintained by hygromycin B selection. cently (Kienzle et al., 1996). Briefly, total RNA was reverse
transcribed with oligo(dT) primers and subjected to alka-
Immunoprecipitations line hydrolysis, and the cDNA was purified using Qiagen
QIAquick spin columns (Qiagen). An aliquot of the RTImmunoprecipitations were performed according to a
reaction was subjected to PCR amplification using eithermodified method of Harlow and Lane (1988). Briefly, cells
the RBP-2N-specific primers 2N-F (5*-ATGGCGCCTGTT-were resuspended in NP-40 lysis buffer (50 mM Tris –
GTGACAGG-3*) and Jk-R (5*-TCCGCTGCCCATAG-3*) orHCl, pH 8; 150 mM NaCl; 1% NP-40; 1 mM PMSF; 10
the RBP-Jk-specific primers Jk-F (5*-ATGGACCACACG-mg/ml aprotinen; 10 mg/ml leupeptin), incubated on ice
GAGGGCT-3*) and Jk-R. PCR amplification was per-for 30 min with occasional mixing, and then centrifuged
formed using the following conditions: 947 for 20 sec, 607at 10,000 g for 10 min at 47. The supernatant was pre-
for 30 sec, 727 for 20 sec, for either 35 or 40 cycles. Thecleared with either protein A–Sepharose or protein G –
products were separated on a 2.7% agarose gel andSepharose (25 ml/200 ml of supernatant) for 1 hr at 47
visualised. The efficacies of the primers were examinedwith constant rocking. Five micrograms of appropriate
by performing PCR on serial dilutions (1:5) of cloned RBP-antibody was added to 200 ml of supernatant (2 1 106
2N and RBP-Jk. An identical quantity of cloned RBP-2Ncells) and the mix was incubated for 2 hr at 47 with
and RBP-Jk was used to do the serial dilutions. The samerocking. Twenty-five microlitres of either protein A–Seph-
PCR conditions were used as stated above; however,arose or protein G–Sepharose was added and then incu-
only 25 cycles of PCR amplification were used.bated for 1 hr at 47 with rocking. The samples were then
centrifuged at 10,000 g for 1 min, the supernatant was
discarded, and the pellet was washed twice with 1.5 ml RESULTS
of NP-40 lysis buffer. The pellet was resuspended in 25
Interaction of EBNA-3 with RBP-Jk in vivoml SDS–PAGE loading buffer, heated to 857 for 10 min,
and centrifuged at 10,000 g for 5 min, and 10 ml of the To identify cellular and viral proteins that may specifi-
supernatant was electrophoresed on 7.5% polyacryl- cally interact with the EBNA-3 protein, we utilised the
amide–SDS gels. yeast two-hybrid system (Clontech). Following sequential
transformation of the yeast plasmid pGBT9-E3 (express-
Immunoblotting
ing EBNA-3) and the GAL4 activation domain cDNA li-
brary vector into yeast strain HF-7c, resultant coloniesBriefly, cell lysates were prepared by resuspending
cells in sample buffer (2% SDS; 5% a-monothioglycerol; were screened using the b-galactosidase filter assay. b-
Galactosidase-positive clones were then verified ac-10% glycerol; 60 mM Tris –HCl, pH 6.8; 0.001% bromophe-
nol blue) then sonicated before heating to 957 for 10 min. cording to the manufacturer’s instructions. Sequence
analysis of a clone positive in the final b-galactosidaseEither protein extracts from 2 1 105 cells or immunopre-
cipitates were electrophoresed on a 7.5% polyacrylamide filter assay identified a truncated form of the RBP-Jk pro-
tein, which began at the 3* end of exon 5 and extendedgel and then electrotransferred onto Hybond-ECL nitro-
cellulose (Amersham, UK). The membrane was blocked through to exon 11. Since isoforms of RBP-Jk differ in
the first exon, it was not possible to determine with whichfor 1 hr at room temperature with blocking buffer [5%
skim milk in phosphate-buffered saline (PBS)] and then isoform of RBP-Jk EBNA-3 was interacting. A similar
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TABLE 1clone, as well as a number of full length clones encoding
RBP-2N, were recently isolated from the yeast two-hybrid Comparison of the in Vivo Interaction between EBNA-3, EBNA-4,
system when the same LCL cDNA library was cotrans- or EBNA-6 with the Different RBP-2N Clones Isolated from the LCL
cDNA Library Screenformed with a vector expressing the EBNA-6 protein
(Young et al., submitted). This result suggests that the
b-major isoform of RBP-Jk in B lymphocytes could be
Galactosidase
RBP-2N. RBP-2N clone unitsa
Predominance of the RBP-2N isoform in B cell lines EBNA-3A RBP-2N full length 118.51 { 10.93
RBP-2N truncation (aa 159–487) 64.32 { 0.67
Primers which discriminate between the first exons of EBNA-6 RBP-2N full length 26.03 { 1.52
RBP-2N and RBP-Jk were used in RT-PCR to determine RBP-2N truncation (aa 159–487) 3.85 { 0.29
EBNA-4 RBP-2N full length 4.99 { 0.95the predominant isoform expressed in EBV-positive and
p53/SV40 TAgb 52.17 { 4.14-negative lymphoid and myeloid cell lines (Fig. 2A). The
major PCR product generated from all of the lymphoid a b-Galactosidase units are expressed as the mean { the standard
cell lines assayed had the same migration pattern as the error from four separate clones processed in duplicate in two separate
PCR-amplified RBP-2N-positive control. PCR amplifica- transformations.
b Internal positive control supplied within the yeast two-hybrid kit.tion of cDNA from the myeloid leukaemic cell line, HL-
60, also resulted in the production of the 200-bp RBP-
2N. The 240-bp DNA product expected from RBP-Jk was
served between the EBNA-3 or the EBNA-6 protein andnot detected in any of the cell lines except QIMR-KT/
the RBP-2N truncation. These results indicate that theB95.8 LCL, and then only using 40 cycles of PCR amplifi-
interaction between RBP-2N and EBNA-3 leads to greatercation (Fig. 2A, panel 10b). In contrast, RBP-2N could be
levels of reporter gene activity than that observed foramplified using 35 cycles of PCR amplification. Contami-
EBNA-4 or EBNA-6.nation by genomic sequences was unlikely as the primer
pairs span two large introns of RBP-2N and RBP-Jk (Ama-
waka et al., 1993). Each of the fragments generated by EBNA-3 binds to RBP-2N differently from EBNAs-2,
PCR amplification were sequenced using the common -4, and -6
3* reverse primer (Jk-R) to confirm their identity. The weak
band above RBP-2N was shown by sequence analysis While previous studies have suggested that EBNA-2,
to be another isoform of RBP-Jk, aPCR-3, previously iden- -3, -4, and -6 all bind to RBP-Jk in vitro, there is limited
tified by Amakawa et al. (1993). To confirm that the prim- information regarding how these proteins interact with
ers have similar efficiencies to amplify their respective this protein. To determine if the interaction between
targets, serial dilutions of the RBP-2N- and RBP-Jk-posi- EBNA-3 or EBNA-4 and RBP-2N was mediated through
tive controls were subjected to PCR amplification using the same regions of RBP-2N, a series of truncations of
the same cycle number. As demonstrated in Fig. 2B both RBP-2N (see Fig. 1) was constructed. These truncations
sets of primers were able to amplify products at a similar were cloned into the GAL4 activation domain vector and
DNA dilution. These results indicate that the RBP-2N iso- cotransformed into yeast along with pGBT9-E3 or pGBT9-
type of RBP-Jk predominates in B cell lines and would E4. The interaction of EBNA-3 or -4 with these deletion
explain why EBNA-3, -4, and -6 were found to interact mutants of RBP-2N was measured using the b-galactosi-
with this isoform of RBP-Jk. dase filter assay. The construct expressing EBNA-4 inter-
acted with the full length RBP-2N and with truncations
EBNA-3 leads to greater b-galactosidase activation corresponding to amino acids 159–487 and 159–331.
when bound to RBP-2N than does EBNA-4 or EBNA-6 Therefore, the minimal region of RBP-2N necessary for
interaction with EBNA-4 appeared to be contained withinTo compare the relative binding activities of EBNA-3,
amino acids 159–331, which is similar to the region to-4, or -6 with RBP-2N the quantitative ONPG b-galactosi-
which EBNA-2 and -6 bind (Hsieh and Hayward, 1995;dase assay was used (Miller et al., 1972). From the re-
Young et al., submitted). Only the full length and G9 trun-sults presented in Table 1, it was apparent that when
cation of RBP-2N (amino acids 159–487) demonstratedEBNA-3 binds to full length RBP-2N, b-galactosidase ac-
interaction with EBNA-3 as determined by b-galactosi-tivity was 4-fold and 24-fold more than when RBP-2N
dase activity. The inability to define a minimal region ofinteracts with EBNA-6 or EBNA-4, respectively. Of partic-
RBP-2N to which EBNA-3 binds suggested that EBNA-3ular interest, the interaction between EBNA-3 and RBP-
may have more than one site of interaction with RBP-2N also leads to 2-fold greater b-galactosidase activity
2N. However, it was evident from these results that thethan the interaction between murine p53 and SV40 large
interaction of EBNA-3 with RBP-2N was different fromT antigen (positive control supplied with the yeast two-
hybrid kit). Lower b-galactosidase activities were ob- that seen with the other EBNA proteins.
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FIG. 1. Representation of the RBP-2N deletion mutants and the level of b-galactosidase detected for each construct in the presence of EBNA-3
or EBNA-4. Black bars indicate the GAL4 activation domain protein which is expressed in fusion with RBP-2N. Lightly shaded bars represent the
region of RBP-2N expressed and in brackets are the corresponding amino acids for each deletion mutant in comparison to the full length RBP-2N.
The level of b-galactosidase activity is indicated by plus or minus.
EE3B; described in Kienzle et al., 1996b). Due to theCoimmunoprecipitation of A- and B-type EBNA-3 with
conservation of exons 2–11 between RBP-2N and RBPJk,RBP-2N/RBP-Jk in vitro
it was highly probable that the RBP-Jk antisera recog-
Immunoprecipitation assays were used to confirm that nised both proteins. EBNA-3 monoclonal antibodies were
the EBNA-3 interaction with RBP-2N also occurred in a used to immunoprecipitate EBNA-3A and EBNA-3B from
B-cell environment. As RBP-2N-specific antibodies were their respective cell lysates. Following electrophoresis
unavailable, antibodies raised against RBP-Jk (Sakai et and transfer of the immunoprecipitates, the membrane
al., 1995) were used to coimmunoprecipitate EBNA-3 and was probed with RBP-Jk antisera to detect RBP-2N/Jk.
RBP-2N from cell lysates prepared from dG75 cells trans- The results show that RBP-2N/Jk was specifically coim-
munoprecipitated with EBNA-3A and EBNA-3B fromfected with either A- or B-type EBNA-3 genes (EE3A,
FIG. 2. (A) RT-PCR amplification of RBP-2N and RBP-Jk cDNAs from haemopoetic cell lines. The following cell lines were analysed for the
presence of RBP-2N (lanes 1) or RBP-Jk (lanes b): BJAB (panel 1); HL-60 (panel 2); dG75 (panel 3); the EBNA-3-expressing dG75 cells EE3-F5 (panel
4), MUTU I (lane 5), and MUTU III (lane 6); the LCLs QIMR-ISM/Wil (lane 7), QIMR-PGP/BL74 (panel 8), and QIMR-KT/B95.8 (panels 10 and 11). The
positions of the RBP-2N and RBP-Jk cDNA fragments are indicated by the arrows. Lanes 9a and 9b are the water controls for each set of primers.
Lane M corresponds to the DNA markers, lane /2N shows the band amplified from cloned RBP-2N, and lane / Jk shows the band amplified from
the cloned RBP-Jk. Note that panels 1 to 10 were performed using 40 cycles of PCR amplification, while 35 cycles were used for panel 11. (B) RT-
PCR amplification of RBP-2N and RBP-Jk products from serial dilutions (1:5) of cloned RBP-2N and RBP-Jk. Serial dilution of RBP-Jk (lanes 1–5),
RBP-2N (lanes 7–11), and respective water controls (lanes 6, 12). M corresponds to the DNA marker lane.
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Jk share core DNA binding consensus sequences, their
target sites are slightly different, 5*-TGGGAAAGAA and
5*-GTGGGAA for RBP-2N (Dou et al., 1994) and RBP-Jk
(Ling et al., 1994), respectively. Exons 2–11 of RBP-2N
and RBP-Jk are homologous (Amakawa et al., 1993), and
this is the region to which the EBNA-2 (Hsieh and Hay-
ward, 1995), -3, -4 (Fig. 1 and Table 1), and -6 (Young
et al., submitted) bind. Johannsen et al. (1996) recently
demonstrated that these EBNAs bind preferentially to the
smaller RBP-Jk isoform in BL cells, suggesting that the
interaction between the EBNAs and RBP-Jk is isoform
dependent. The study suggested that the smaller isoform
FIG. 3. Immunoprecipitation and Western blotting of dG75 cells ex- is a different splice variant (PCR3); however, the results
pressing EBNA-3A or EBNA-3B. (A) EBNA-3 immunoprecipitation per- herein and of others (Zhao et al., 1996) would suggestformed on dG75 vector control cells (lane 1), dG75 cells expressing
that RBP-2N is the smaller isoform with which the EBNAsEBNA-3A, EE3-F5 (lane 2), and dG75 cells expressing EBNA-3B—bulk
interact. Therefore, studies focusing on the effect of theculture (lane 3). Membranes were probed with anti-RBP antibodies to
detect coprecipitated RBP-2N/Jk. Lane 4 contains total cell lysate from EBNAs on RBP-2N/RBP-Jk activity are likely to give dif-
dG75 cells expressing EBNA-3B, demonstrating the apparent size of fering results depending upon the isoform of RBP-Jk
RBP-2N/Jk. (B and C) Total cell lysates from dG75 vector control cells used. These types of studies should therefore utilise(lane 1), dG75 cells expressing EBNA-3A, EE3-F5 (lane 2), dG75 cells
RBP-2N, the predominant isoform in B lymphocytes.expressing EBNA-3B, EE3B-5 (lane 3), and dG75 cells expressing
We present evidence that an interaction between RBP-EBNA-3B—bulk culture (lane 4) probed with human sera reactive
against the EBNA-3 protein (B) or anti-RBP antibody recognising the 2N/Jk and EBNA-3A or EBNA-3B occurs in vitro by immu-
RBP-2N protein (C). noprecipitation (Fig. 3). The EBNA-3 A and B type have
90 and 84% identity at the nucleotide and amino acid
levels, respectively (Sample et al., 1990), which coulddG75 cells transfected with either EBNA-3A or EBNA-3B
result in differences in binding to RBP-2N. There is 80%(Fig. 3A, lanes 2 and 3), whereas in dG75 cells trans-
amino acid identity within the first 138 amino acids, whichfected with the control vector alone no RBP-2N/Jk could
corresponds to the region of EBNA-3 suggested to bindbe coimmunoprecipitated by EBNA-3 antisera (Fig. 3A,
RBP-Jk (Robertson et al., 1996). However, the EBNA-3Alane 1). The presence of RBP-2N/Jk and EBNA-3 in the
and EBNA-3B proteins demonstrated similar interactionstotal cell lysates is shown in Figs. 3B and 3C, respec-
with RBP-2N/Jk in the immunoprecipitations. It will be oftively. These results demonstrate that both the EBNA-3A
interest to compare the difference between EBNA-3A andand the EBNA-3B proteins interact with RBP-2N/Jk in a
EBNA-3B interaction with RBP-2N in the yeast two-hybridcellular environment, and confirm the results from the
system as well. While the significance of this result isyeast two-hybrid system.
difficult to predict, it may have important implications in
terms of the previously reported finding that A-type virus
DISCUSSION
has a greater B cell transformation efficiency than B-type
virus (Rickinson et al., 1987).Using the yeast two-hybrid system EBNA-3A was
found to interact with a truncated form of RBP-Jk. Earlier The EBNA-3 family of proteins, EBNAs-3, -4, and -6,
are all expressed in B cells latently infected with EBV,studies (Young et al., submitted) demonstrated that
EBNA-6 interacted with the RBP-2N isoform of RBP-Jk, suggesting that they play a role in maintaining or control-
ling B cell transformation. As the proteins share structuralsuggesting that RBP-2N may be the predominant isoform
found in B lymphocytes. To investigate this further RT- homology at the DNA and amino acid level it is not sur-
prising that they all interact with the same DNA-bindingPCR was performed using primers specific for either
RBP-2N or RBP-Jk. The results indicated that the RBP- protein RBP-2N (Young et al., submitted; Fig. 1). However
there is limited information regarding how these proteins2N isoform was expressed at much higher levels than
RBP-Jk in a number of different BL cell lines and LCLs interact with and regulate RBP-2N activity. It is evident
that EBNA-2 (Hseih and Hayward, 1995), -4 (Fig. 1), and(Fig. 2). In support of this finding, RBP-2N mRNA was
previously found to be transcribed 10- to 20-fold higher -6 (Young et al., submitted) all interact with the same
region of RBP-2N/RBP-Jk, suggesting that the proteinsthan the RBP-Jk mRNA in mouse pre-B cells. RBP-2N and
RBP-Jk result from different initiation sites and alternative compete for binding. Studies have shown that EBNA-2
-mediated transactivation can be inhibited by EBNA-6,splicing (Amakawa et al., 1993), which may be dependent
on cell type. The first exon of each protein is different through direct interaction of EBNA-6 with RBP-Jk (Robert-
son et al., 1995). In addition the EBNA-3, -4, and -6 pro-and may play a role in altering protein interactions or
DNA binding specificity, possibly resulting in the regula- teins have been shown to individually repress the EBNA-2
-mediated transactivation of the viral terminal protein 1tion of different sets of genes. While RBP-2N and RBP-
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gene promoter (Le Roux et al., 1994). Although the EBNA- 2 through a number of different mechanisms: (1) altering
the specificity of RBP-2N for DNA; (2) the interaction be-3 interaction with RBP-2N varies from that of EBNA-4
and -6, it is possible that EBNA-3 could compete with tween EBNAs and RBP-2N may lead to conformational
changes in the EBNAs that allow the complex to interactthe other EBNAs for binding to RBP-2N and may have
different effects on RBP-2N activity. That all these EBNAs with different proteins or DNA promoters; or (3) the inter-
action may lead to the transcriptional activation of thoseinteract with the same DNA-binding protein indicates that
there is great complexity within the system and suggests genes normally repressed by RBP-2N, by preventing
RBP-2N binding to DNA. Further studies will need to bethat RBP-2N plays a crucial role in the regulation of ex-
pression of genes that lead to either B cell activation or completed before EBNA/RBP-2N-regulated gene expres-
sion and transcription are defined.cellular transformation.
The variation in b-galactosidase activity observed be- In the early stages of B cell immortalisation by EBV
the presence of EBNA-2 is essential. EBNA-2 can upreg-tween EBNA-3, -4, or -6 when interacting with RBP-2N
(Table 1) suggests that there are profound differences ulate the levels of LMP-1, which when overexpressed is
toxic to cells (Hammerschmidt et al., 1989); this wouldbetween the EBNA-3 family proteins. It should be noted
that the level of b-galactosidase activity observed may suggest that EBV-transformed B cells require a mecha-
nism to modulate EBNA-2-mediated transactivation ofnot directly correlate with binding affinities for a number
of reasons. The level of b-galactosidase activity can be LMP-1. At least one function of the EBNA-3 family pro-
teins appears to be to regulate the activity of EBNA-2 (Leinfluenced by the level of expression of each protein;
however, as the promoters for EBNA-3, -4, and -6 are Roux et al., 1994). This suggests that the expression of
the EBNA-3 family of proteins must be regulated in orderidentical and as assays for activity were performed on
multiple clones isolated from independent transforma- to maintain an activated transformed cellular state. Given
the strength of b-galactosidase activation observed fortions (Table 1), it is likely that the expression levels are
similar. It is possible that the interaction between EBNA- the interaction between EBNA-3 and RBP-2N, which is
considerably higher than that observed for EBNA-4 or3 and RBP-2N brings an association of the GAL4 activa-
tion and DNA-binding domains that allows greater levels -6, it is likely that expression of each of the EBNA-3, -4,
and -6 genes is regulated independently. It is apparent,of b-galactosidase to be activated than when EBNA-4
or -6 interact with RBP-2N. The strength/affinity of the therefore, that for B cells to persistently maintain EBV
and remain in an activated cellular state, the cells wouldinteractions could also lead to variations in b-galactosi-
dase activity, where stronger interactions lead to greater require a complex network of regulatory mechanisms
controlling the expression of EBNA-2, -3, -4, and -6 andactivity. It is possible then that EBNA-3 could bind to
RBP-2N more strongly than EBNA-4 or -6. LMP-1.
To fully understand how EBV modulates the cellularEBNA-4 demonstrated the weakest b-galactosidase
activation when interacting with RBP-2N and bound to gene regulator RBP-2N to circumvent normal control
mechanisms and drive cells to activation and prolifera-the same region of RBP-2N as EBNA-6, suggesting that
the RBP-2N functional activity of EBNA-4 may be redun- tion, it will be important to delineate the effects that each
of the EBNA proteins has on RBP-2N activity. In addition,dant. This would be in agreement with the findings that
EBNA-4 was not essential for lymphocyte infection or the regulation of the EBNA proteins and the competition
between the EBNAs for binding to RBP-2N needs to begrowth transformation (Tomkinson et al., 1992). The inter-
action between EBNA-3 and RBP-2N leads to the great- addressed.
est b-galactosidase activation, suggesting that this inter-
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